INVO Bioscience, Inc. received a notice from Nasdaq about not meeting the minimum bid price requirement of $1.00 per share, giving them until May 17, 2025, to regain compliance; additionally, the company will restate its financial statements due to an error in lease liability valuation, but this does not affect revenue or operations.